PKD1L2

Across TCGA pan-cancer cohorts, PKD1L2 Mutation is linked to patient survival in 16 of 34 cancer types, making it a survival-associated PKD1L2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PKD1L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PKD1L2 expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

KICH, KIRP, and LUSC are the cancer types where PKD1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	OS	Median	All	0.161	0.881	<.001	24	view →
KIRP	DFS	Median	III,IV	0.040	0.703	<.001	12	view →
LUSC	DFS	Median	All	0.197	0.519	.008	12	view →
STAD	DFS	Median	II,III,IV	0.904	0.595	.035	10	view →
COAD	OS	Median	II,III,IV	0.605	0.863	.001	9	view →
PAAD	DFS	Median	All	0.100	0.505	.004	6	view →
READ	DFS	Median	All	0.431	0.806	.040	6	view →
PRAD	DFS	Median	All	0.110	0.776	<.001	6	view →
ESCA	OS	Median	All	1.000	0.442	.034	6	view →
LUAD	OS	Median	III,IV	0.224	0.667	.005	6	view →
BLCA	DFS	Median	IV	1.000	0.452	.024	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

PKD1L2–KICH (OS)

Open the KICH breakdown →